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Abstract
Background: To evaluate the safety and efficacy of the completely retroperitoneoscopic nephroureterectomy
(CRNU), a retrospectively comparative study between completely and traditionally retroperitoneoscopic
nephroureterectomy (TRNU) was done in a single center.
Methods: From January 2014 to December 2014, 107 patients with upper tract urothelial cancer (UTUC) underwent
CRNU. The kidney was retroperitoneoscopically dissected and the bladder cuff was cut by endoscopic gastrointestinal
automatic stapler, and the specimen was removed from a 6-cm incision by posterior axillary line. Demographic,
perioperative, and follow-up data were collected and compared retrospectively with 110 patients undergoing TRNU.
Results: The patients’ characteristics between the two groups were not statistically different (p > 0.05), and all patients
successfully received the procedure. The mean operative time (106 ± 37.9 versus 199 ± 69.1 min, p < 0.0001), the mean
estimated blood loss (47.2 ± 82.4 versus 166.9 ± 250.9 ml, p = 0.002), and the mean hospital stay (6.1 ± 3.5 versus 8.1 ± 3.
3 days, p = 0.03) of the CRNU group decreased significantly compared to the traditional group. The operative time was
not affected by gender. No open conversion and major complications occurred. The surgical margin of the ureter was
all negative. The mean follow-up time was 13.4 months for the CRNU group and 37.5 months for the TRNU group. All
follow-up patients in the CRNU group were alive without local recurrence. No cases of port site metastasis and local
recurrence were observed in both groups. Bladder tumor recurrence occurred in 4 patients of the CRNU group and 21
patients of the TRNU group.
Conclusions: The CRNU using an endoscopic gastrointestinal automatic stapler to manage the bladder cuff is feasible
and advantageous in decreasing the operative time, the blood loss, and the hospital stay. However, a larger sample
and longer follow-up time will be still required.
Keywords: Retroperitoneal, Retroperitoneoscopic nephroureterectomy, Upper tract urothelial cancer
* Correspondence: doczhz@aliyun.com; zhoulqmail@sina.com
†Equal contributors
1Department of Urology, Peking University First Hospital, No. 8 Xishiku St,
Xicheng District, Beijing 100034, China
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Yao et al. World Journal of Surgical Oncology  (2016) 14:171 
DOI 10.1186/s12957-016-0924-3
Background
The golden standard surgical treatment for non-metastatic
upper tract urothelial carcinoma (UTUC) is open radical
nephroureterectomy with resection of the distal ureter and
bladder cuff [1]. Since Clayman et al. firstly described the
laparoscopic nephroureterectomy, it has been confirmed to
be oncologically equally effective compared to open radical
nephroureterectomy [2].
In our center, combining the retroperitoneoscopic
nephrectomy with open distal ureterectomy with a blad-
der cuff has been performed to minimize the surgical
mortality. In this traditional way, the patient’s position
has to be changed from lateral position to supine
position during the surgery while re-disinfection of open
incision is also needed. Since January 2014, in order to
improve the surgical procedure, we have developed a
new surgical procedure defined as completely retroperi-
toneoscopic resection of the kidney and distal ureter
with bladder cuff. We presented our initial evaluation of
the safety and the efficacy of this procedure compared to
the traditionally surgical procedure.
Methods
From January 2014 to December 2014, 46 males and
61 females with UTUC of the renal pelvis and/or
ureter received the completely retroperitoneoscopic
nephroureterectomy (CRNU) performed by the same
surgical team. The patients were preoperatively
diagnosed by computerized tomography (positive rate,
103/107, 96.3 %), fluorescence in situ hybridization
(positive rate, 92/107, 86.0 %), the urinary cytology
(positive rate, 63/107, 58.9 %), or ureteroscopy (positive
rate, 20/20). In these examinations, the ureteroscopic
biopsy was not the essential examination, unless it was
used for diagnostic uncertainty and the patient’s strongly
requirement.
The data were retrospectively collected, including
demographic data (age and gender), body mass index
(BMI), the overall operative time (from the beginning
to the end of the whole surgery, including the time
of re-position, re-disinfection, and changing televi-
sion monitor), the intraoperative blood loss, compli-
cations, open conversion rate, hospitalization stay,
the removal time of the catheter and the drainage,
the pathological outcome, the follow-up time, and
the follow-up results. Data of 110 patients received
traditionally retroperitoneoscopic nephroureterectomy
(TRNU) from March 2010 to June 2014 operated by
the same surgical team were also collected for
comparisons.
Informed contents were accepted and signed off by all
patients and their family members before surgery. The
study was approved by the institutional review board
from Peking University First Hospital.
Surgical technique
All patients in the CRNU group successfully received the
surgery. After the induction of general anesthesia, a
transurethral catheter was inserted. The patient was placed
in a side appropriate lateral decubitus position, and the
waist was raised by placing a square mat under the waist.
A 3-cm incision was made 2 cm below the crossing
point of the posterior axillary line and the 12th rib
margin (point a, see Fig. 1a, b). The muscle was bluntly
dissected from the incision by a forceps until the extra-
peritoneal fat could be seen. The retroperitoneal space
was expanded by the surgeon’s forefinger. A balloon was
made from a size 8 surgical glove and tied to a 50-ml
injector. Then, the homemade balloon was placed into
the retroperitoneal space and inflated with 600 to
800 ml of air to get an appropriate working space.
Guided by the surgeon’s forefinger, two 12-mm trocars
were inserted at point b and point c (Fig. 1a, b). The
trocar at point b was used as the camera port. Then, a
12-mm trocar was placed from the 3-cm incision which
was sutured partially to fix the trocar.
Gerota’s fascia was opened after the extraperitoneal fat
was dissected, and the dorsal side of the kidney was
exposed outside the perirenal fat capsule. The upper
segment of the ureter was dissected and clamped by
Hem-o-lok. Then, the kidney was retroperitoneally
dissected, including the renal vein, renal artery, the
upper pole, the lower pole, and the ventral side of the
kidney (Fig. 2a). The adrenal gland was reserved.
After, the ureter was dissected to the level of the iliac
crest. The positions of the television monitor, surgeon,
and assistant were changed (Fig. 1c, d). One more trocar
was placed at McBurney’s point (point d, see Fig. 1a, b) if
the affected side was on the right side (or the symmetrical
equivalent to McBurney’s point for the tumor on the left
side). The camera port was changed from point b to point
c. Two trocars at point b and point d were used as opera-
tive ports. The ureter should be continuously dissected
until to the vesicoureteral junction (Fig. 2b). For the
female patient, uterine artery was cut after clipped by
Hem-o-lok. The detrusor muscle was incised along the
ureter in different directions while pulling the proximal
ureter to obtain a 3-cm-wide bladder cuff around the
ureteral orifice (Fig. 2c, d). Then, the distal ureter with
bladder cuff was transected by a flexible endoscopic
gastrointestinal automatic stapler (Endo-GIA) (Fig. 2e, f ).
Lymphadenectomy could be performed if needed. The
specimen was put into an endoscopic specimen bag. The
incision of the port on the posterior axillary line was
extended to be a 6-cm incision to remove the specimen.
At that time, the specimen must be confirmed to contain
the required bladder cuff by the surgeon. After the con-
firmation of the complete removal of the bladder cuff, a
F20 drain was placed into the pelvic cavity through port b.
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Fig. 2 Operative view of main surgical steps. u ureter, k kidney, v renal vein, a renal artery. a Nephrectomy and mobilization of proximal ureter.
The ureter is clamped by Hem-o-lok. b Distal ureter is dissected in the pelvic cavity. c Distal ureter with the bladder cuff marked with black dotted
line. d The cutting margin of the required bladder cuff marked with yellow dotted line. e The bladder cuff is cut by endoscopic gastrointestinal
automatic stapler. f The cutting margin of the required bladder cuff marked with yellow dotted line
Fig. 1 Trocar distribution and change of operative position (affected side is on the right in this example). a, b Point a: 2 cm below the crossing
point of the posterior axillary line and the 12th rib margin. Point b: 3 cm ventrally to the crossing point of the midaxillary line and iliac crest.
Point c: 2 cm below the costal margin in the anterior axillary line. Point d: at the McBurney’s point. c, d The positions of the television monitor,
surgeon, and assistant when nephrectomy with mobilization of the proximal ureter and when distal ureterectomy with bladder cuff excision.
R right, L left, S surgeon, A assistant
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Sometimes, an additional drain tube was put in the renal
bed. At last, the incision and the port sites without
drainages were closed and the drainages were fixed. The
patient-controlled analgesia pumps are routinely used
after surgery if there is no contraindication.
Ninety-five patients received single bladder instillation of
the pirarubicin (dosage, 40 mg) or the epirubicin (dosage,
50 mg) within 48 h after surgery. No bladder leakage
occurred. All patients received cystoscopic observation
3 months after surgery, and no stone formation was seen
in the bladder. The cystoscopy observation also showed
that the bladder incision healed well, and no ureteral orifice
was found on the affected side (Fig. 3). Further follow-up
consisted of cystoscopy, urinary cytology every 3 to
6 months, and computed tomography every 6 months.
Lymphadenectomy is still not routinely performed
at RNU. Only three patients of invasive UTUC in the
CRNU group whose preoperative image indicated the
suspicious enlarged lymph nodes received regional
lymphadenectomy. No patient in the TRNU group
received lymphadenectomy.
Statistical analysis was performed using Mann–Whitney
U test and Student t test to evaluate statistical differences
between different groups. Difference was considered
statistically significant if p value was <0.05.
Results
The comparisons of patient’s characteristics between
CRNU and TRNU are shown in Table 1, and no signifi-
cant differences are detected in gender, age, BMI, and
operative side (p > 0.05, Table 1).
The surgical outcomes of the two groups are also shown
in Table 1. The mean overall operative time (106.0 ± 37.9
versus 199.5 ± 69.1 min, p < 0.0001), the mean estimated
blood loss (47.2 ± 82.4 versus 166.9 ± 250.9 ml, p = 0.002),
the mean hospital stay (6.1 ± 3.5 versus 8.1 ± 3.3 days,
p = 0.03) of the CRNU group were significantly reduced
compared to TRNU while the overall operative time
was not affected by gender (p > 0.05, Table 1), and no
open conversion occurred. No major complications
were observed in both groups except four patients in
the CRNU group, and seven patients in the TRNU
group suffered urinary tract infection and been cured
with antibiotics for 1 week. Lymphatic leakage occurred
in four patients of the CRNU group and two patients of
the TRNU group.
The pathological diagnoses are shown in Table 1. The
surgical margin of the ureter was all negative. In three
patients who received lymphadenectomy, two patients
had positive lymph nodes and one patient had negative
result. Two patients in the CRNU group and four
patients in the TRNU group were lost to follow-up
because we could not connect with them. The mean
follow-up time was 13.4 ± 2.1 months in the CRNU
group and 37.5 ± 15.9 months in the TRNU group. All
follow-up patients in the CRNU group were alive
without local recurrence. No cases of port site metastasis
and local recurrence were observed in both groups.
Bladder tumor recurrence occurred in four patients in
the CRNU group treated with transurethral resection
and in 21 patients in the TRNU group.
Discussion
Although the golden standard treatment for localized
high-risk UTUC is still the radical nephroureterectomy
with excision of the bladder cuff [1], with extensive pro-
gress of minimally invasive techniques, the laparoscopic
nephroureterectomy (LNU) has evolved into an effective
alternative to open nephroureterectomy (ONU) [3]. More
and more studies have supported that LNU has a compar-
able oncological outcomes to ONU. In addition, LNU can
reduce the blood loss, hospital stay, and post-operative
pain compared with ONU [4–9]. In this study, the mean
operative time, the mean estimated blood loss, and the
mean hospital stay in the CRNU group are further
decreased compared to the TRNU group.
The radical nephroureterectomy can be divided into
two main steps: nephrectomy with mobilization of the
proximal ureter and distal ureterectomy with bladder
cuff excision. In our center, traditionally, the nephrec-
tomy and the mobilization of the proximal ureter are
performed by retroperitoneal approach, but the distal
ureterectomy with bladder cuff is performed by open
approach. The patient’s position needs to be changed
from lateral position to supine position, and one more
Fig. 3 The healed bladder incision marked with the red arrow is no
ureteral orifice on the affected side when under cystoscopy
examination 3 months after surgery
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Table 1 Patient’s characteristics, surgical results, and follow-up outcomes of CRNU and TRNU
Parameter CRNU TRNU p value




Median age, year (range) 71 (55–82) 71 (52–88) 0.51
Mean BMI, kg/m2 (range; ±SD) 23.2 (18.1–28.1; ±2.8) 23.5 (17.6–29; ±2.9) 0.50









Multiple location 6 5
Mean overall operating time, min (range; ±SD) 106.0 (46–216; ±37.9) 199.5 (100–416; ±69.1) <0.0001
Male 105.0 (76–172; ±25.7) 218.3 (128–416; ±71.9) <0.0001
p value (Male versus Female) 0.93 > 0.05 0.06 > 0.05
Female 106.5 (46–216; ±42.3) 185.1 (100–410; ±63.2) <0.0001
Mean estimated blood loss, ml (range; ±SD) 47.2 (5–400; ±82.4) 166.9 (20–1450; ±250.9) 0.002
RNU with lymph node dissection
No. of patients 3 No
Open conversion No No
Intraoperative and postoperative complications
(n/Clavien Classification)
UTI 4/grade II 7/grade II
Lymphatic leakage 4/grade I 2/grade I
Others 0 0
Single bladder instillation of chemotherapy 95 97
The removal time of drain after surgery, days (range; ± SD) 4.0 (2–17; ±3.0) 4.2 (2–12; ±1.5) 0.79
Mean hospital stay, days (range; ±SD) 6.1 (3–21; ±3.5) 8.1 (4–26; ±3.3) 0.03
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disinfection of the incision should be performed. To
facilitate this process and reduce the operative time, we
tried to perform a completely retroperitoneal approach
with no need to change the patient’s position. By this
way, we just take about 3 to 5 min to adjust during the
midway surgery and the operative time dramatically
decreases.
The management of distal ureter is a very important
step in either laparoscopic procedure or open procedure.
It may be an independent predictor of oncological out-
come. In 2014, Krabbe et al. reported that the surgical
management of the distal ureter without excision of a
transvesical bladder cuff resulted in significantly worse
non-intravesical recurrence (IVR)-free survival and
cancer-specific survival but had no influence on IVR
[10]. This study moved us to standardize the resection
of bladder cuff.
There have been many approaches to manage the
bladder cuff, including transvesical, extravesical, and
endoscopic procedures [3, 4, 11–14]. Among these
methods, no differences in non-bladder recurrence and
survival exist; however, the endoscopic approach has a
higher rate of intravesical recurrence [11].
In 1995, McDougall et al. firstly reported the extravesi-
cal transection of the distal ureter with the bladder cuff
using an Endo-GIA which is an extravesical approach
[4]. Then, Yoshino et al. reported this method to manage
the bladder cuff by completely retroperitoneal approach
in 2003 [14]. They concluded that the Endo-GIA was an
efficient and low-risk procedure. Both our technique and
Yoshino’s technique are the completely retroperitoneal
approach. But the number of the ports (four ports in our
technique and five ports in Yoshino’s technique) and the
procedures to dissect the distal ureter are different. As
the complete retroperitoneal approach does not enter
into the abdominal cavity, the abdominal cavity implant-
ation metastasis can be avoided maximally. But the
biggest limitation of these studies and this study was the
lack of long-term follow-up.
In addition, another disadvantage was that the complete
removal of the bladder cuff could not be confirmed using
the Endo-GIA [14]. So, we must examine whether the
dissected specimen contains the required bladder cuff im-
mediately after the specimen is taken out as a urethral
catheter is inserted before surgery to drain out the urine
to decrease the bladder filling pressure and to avoid the
urine extravasation as much as possible when the bladder
cuff is cut by the Endo-GIA.
Because the urothelium between the staples of Endo-
GIA remains after transection, the incomplete excision
of bladder cuff can lead to a high recurrence rate [15],
and the remaining urothelium may be a source of recur-
rence. So the use of staples is no longer considered as
effective technique for complete and safe bladder cuff
removal in the ICUD-SIU consultation for the treatment
of localized high-risk UTUC updated by 2016 [16].
However, the traditional method of closing the bladder
wall with sutures also faces the risk of 3 to 5 mm of the
remaining urothelium [14].
The staples may be exposed inside the bladder and
lead to stone formation in the long run. However, we
did not found stone formation and the staples under
cystoscopy during follow-up time. Chandhoke et al. also
found neither staples nor stone formation [17].
Generally, surgery on male patients might be more
difficult as the female pelvis is wider than the male’s.
However, in our study, there was no significant statistical
difference (p > 0.05) on the operative time between the
male and the female.
It is reported that 40 % of patients after nephroureter-
ectomy will develop bladder recurrence potentially derived
from implantation of the primary tumor. O’Brien et al.
reported that a single post-operative dose of intravesical
mitomycin C could reduce the risk of a bladder tumor
within the first year after nephroureterectomy [18].
Another prospective randomized phase II by Ito et al. also
reported that the patient who received a single early intra-
vesical instillation of pirarubicin had a lower bladder
Table 1 Patient’s characteristics, surgical results, and follow-up outcomes of CRNU and TRNU (Continued)




The surgical margin of the distal ureter (negative or positive) Negative Negative
Mean follow-up time, month (range; ±SD) 13.4 (6–18; ±2.1) 37.5 (13–63; ±15.9)
No. of patients of follow-up (n) 105 106
Bladder tumor recurrence
No. patients of follow-up (n) 4 21
BMI body mass index, CRNU completely retroperitoneoscopic nephroureterectomy, TRNU traditionally retroperitoneoscopic nephroureterectomy, UTI urinary
tract infection
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recurrence rate than the non-instillation group at 1 year
(16.9 % versus 31.8 %) and 2 years (16.9 % versus 42.2 %)
[19]. In the European Association of Urology guidelines
on UTUC updated by 2015 and the ICUD‑SIU consult-
ation on localized high-risk UTUC updated by 2016, post-
operative instillation of chemotherapy is recommended to
avoid bladder recurrence [1, 16]. In our center, the pa-
tients are generally recommended a single post-operative
intravesical instillation of pirarubicin or epirubicin within
48 h after surgery.
Conclusions
In conclusion, the CRNU using an Endo-GIA to cut
the bladder cuff is advantageous in decreasing opera-
tive time, the blood loss, and the hospital stay. How-
ever, a larger sample, longer follow-up time, and
further analysis are still needed to confirm its onco-
logical outcome.
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